AR116713A1 - COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 - Google Patents

COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3

Info

Publication number
AR116713A1
AR116713A1 ARP190102939A ARP190102939A AR116713A1 AR 116713 A1 AR116713 A1 AR 116713A1 AR P190102939 A ARP190102939 A AR P190102939A AR P190102939 A ARP190102939 A AR P190102939A AR 116713 A1 AR116713 A1 AR 116713A1
Authority
AR
Argentina
Prior art keywords
imidazolindiona
compounds
channel regulators
methyl
attached
Prior art date
Application number
ARP190102939A
Other languages
English (en)
Spanish (es)
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of AR116713A1 publication Critical patent/AR116713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP190102939A 2018-10-16 2019-10-16 COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3 AR116713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18200626 2018-10-16

Publications (1)

Publication Number Publication Date
AR116713A1 true AR116713A1 (es) 2021-06-02

Family

ID=63878368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102939A AR116713A1 (es) 2018-10-16 2019-10-16 COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3

Country Status (21)

Country Link
US (1) US20250304564A1 (cg-RX-API-DMAC7.html)
EP (1) EP3867247B1 (cg-RX-API-DMAC7.html)
JP (1) JP7465868B2 (cg-RX-API-DMAC7.html)
KR (1) KR102854594B1 (cg-RX-API-DMAC7.html)
AR (1) AR116713A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019360017B9 (cg-RX-API-DMAC7.html)
BR (1) BR112021006940A2 (cg-RX-API-DMAC7.html)
DK (1) DK3867247T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988842T3 (cg-RX-API-DMAC7.html)
FI (1) FI3867247T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241318T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068686T2 (cg-RX-API-DMAC7.html)
IL (1) IL282096B2 (cg-RX-API-DMAC7.html)
LT (1) LT3867247T (cg-RX-API-DMAC7.html)
MX (1) MX2021004386A (cg-RX-API-DMAC7.html)
PL (1) PL3867247T3 (cg-RX-API-DMAC7.html)
PT (1) PT3867247T (cg-RX-API-DMAC7.html)
SI (1) SI3867247T1 (cg-RX-API-DMAC7.html)
TW (1) TWI827706B (cg-RX-API-DMAC7.html)
WO (1) WO2020079422A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101487B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
BR112022013339A2 (pt) * 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
EP4384165B1 (en) * 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
KR101862375B1 (ko) 2010-12-06 2018-05-29 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
PL2788339T3 (pl) 2011-12-06 2016-09-30 Pochodne hydantoiny przydatne jako inhibitory KV3
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels

Also Published As

Publication number Publication date
SI3867247T1 (sl) 2024-11-29
FI3867247T3 (fi) 2024-10-30
TWI827706B (zh) 2024-01-01
ES2988842T3 (es) 2024-11-21
HUE068686T2 (hu) 2025-01-28
JP2022505143A (ja) 2022-01-14
TW202035394A (zh) 2020-10-01
WO2020079422A1 (en) 2020-04-23
AU2019360017B2 (en) 2025-03-06
DK3867247T3 (da) 2024-09-16
IL282096A (en) 2021-05-31
KR20210076081A (ko) 2021-06-23
IL282096B1 (en) 2024-03-01
EP3867247A1 (en) 2021-08-25
MX2021004386A (es) 2021-06-04
PL3867247T3 (pl) 2024-12-09
PT3867247T (pt) 2024-09-17
HRP20241318T1 (hr) 2024-12-20
AU2019360017A1 (en) 2021-04-01
EP3867247B1 (en) 2024-07-24
LT3867247T (lt) 2024-11-11
BR112021006940A2 (pt) 2021-07-13
JP7465868B2 (ja) 2024-04-11
AU2019360017B9 (en) 2025-03-27
KR102854594B1 (ko) 2025-09-02
US20250304564A1 (en) 2025-10-02
IL282096B2 (en) 2024-07-01
ZA202101487B (en) 2024-05-30

Similar Documents

Publication Publication Date Title
TWD215802S (zh) 鼻管組合
AR116283A1 (es) Inhibidores del sarcómero cardíaco
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR109349A1 (es) Compuestos y usos
AR113688A1 (es) Proceso para la preparación de compuestos de piridiminio ópticamente activo
AR093937A1 (es) Compuestos quimicos
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR094978A1 (es) Derivados de pirazol agonistas de receptores canabinoides
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
ES2568909T3 (es) Novedosos compuestos antagonistas del receptor de la neuroquinina 1
MX2018014944A (es) Tratamiento para la enfermedad de parkinson.
BR112023023951A2 (pt) Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio
AR084172A1 (es) Derivados aminotriazol hidroxilados como agonistas del receptor alx
MX2017011824A (es) Derivado de morfinano.
AR084173A1 (es) Derivados oxazolil-metileter como agonistas del receptor alx
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
AR100439A1 (es) Derivados de carboxamida
AR105653A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021004386A (es) Compuestos novedosos.
CR20160562A (es) Péptidos como agonistas de la oxitocina
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR119521A1 (es) DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CL2019001617A1 (es) Preparación líquida parenteral que comprende compuesto de carbamato.

Legal Events

Date Code Title Description
FG Grant, registration